Norges Bank Acquires Shares of 84,750 LivaNova PLC (NASDAQ:LIVN)

Norges Bank bought a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 84,750 shares of the company's stock, valued at approximately $3,925,000. Norges Bank owned about 0.16% of LivaNova at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in LIVN. FMR LLC grew its stake in LivaNova by 68.0% in the 3rd quarter. FMR LLC now owns 31,466 shares of the company's stock worth $1,653,000 after acquiring an additional 12,735 shares in the last quarter. Captrust Financial Advisors bought a new stake in LivaNova during the 3rd quarter valued at $217,000. XTX Topco Ltd purchased a new stake in shares of LivaNova in the 3rd quarter worth $550,000. Geode Capital Management LLC grew its position in shares of LivaNova by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock worth $70,676,000 after buying an additional 8,331 shares in the last quarter. Finally, Sanctuary Advisors LLC purchased a new position in shares of LivaNova during the third quarter valued at $219,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Stock Performance

Shares of LivaNova stock traded up $0.37 on Wednesday, reaching $35.17. 56,573 shares of the stock were exchanged, compared to its average volume of 624,110. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $64.48. The business has a 50 day moving average price of $40.84 and a two-hundred day moving average price of $47.08. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of 83.67 and a beta of 0.90.

Wall Street Analysts Forecast Growth

LIVN has been the subject of several recent research reports. Mizuho reduced their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus reduced their price target on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Barclays reduced their target price on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a report on Friday, March 7th. The Goldman Sachs Group cut their price objective on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Finally, StockNews.com raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Tuesday, March 25th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.